Haven: The strategy that didn’t fix healthcareJohn Singer discusses the disbanding of Haven, the joint healthcare venture by Amazon, JP Morgan and Berkshire Hathaway, Share XHaven: The strategy that didn’t fix healthcarehttps://pharmaphorum.com/views-analysis-market-access/haven-strategy-healthcare/
Gene editing: beyond the hypeGenome editing is an exciting but still nascent field, and companies in the area face as many obstacles Share XGene editing: beyond the hypehttps://pharmaphorum.com/r-d/views-analysis-r-d/genome-editing-sangamo-beyond-the-hype/
Sanofi’s Bozidar Jovicevic on how the company is approaching digital therapeuticsPaul Tunnah caught up with Sanofi’s vice president, global head of digital therapeutics at JP Morgan to talk Share XSanofi’s Bozidar Jovicevic on how the company is approaching digital therapeuticshttps://pharmaphorum.com/video/sanofis-bozidar-jovicevic-on-how-the-company-is-approaching-digital-therapeutics/
UCB’s James Musick on embracing digital therapeuticsDigital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it. Share XUCB’s James Musick on embracing digital therapeuticshttps://pharmaphorum.com/views-analysis-digital/ucbs-james-musick-on-embracing-digital-therapeutics/
Millendo’s Julia Owens on leadership in rare diseasesRare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome. Share XMillendo’s Julia Owens on leadership in rare diseaseshttps://pharmaphorum.com/r-d/views-analysis-r-d/millendo-julia-owens-leadership-rare-diseases/
Helsinn’s Riccardo Braglia on the patient perspective in cancer careSwiss cancer care company Helsinn has become unique in the industry by remaining a family business over three Share XHelsinn’s Riccardo Braglia on the patient perspective in cancer carehttps://pharmaphorum.com/views-analysis-oncology/helsinns-riccardo-braglia-patient-perspective-cancer-care/
Pharma highlights from 2019 and a look ahead to 2020Paul Tunnah looks at the trends that defined this year in pharma and what they might mean for Share XPharma highlights from 2019 and a look ahead to 2020https://pharmaphorum.com/views-analysis-patients/pharma-highlights-2019-look-ahead-2020/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
Sage soars on postpartum depression dataSage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on Share XSage soars on postpartum depression datahttps://pharmaphorum.com/news/sage-soars-on-postpartum-depression-data/
